Oct. 24 (Bloomberg) -- Roche Holding AG, the world’s biggest maker of cancer drugs, is seeking more partners for research in China and may form a fifth alliance by December, an executive said.
The Basel, Switzerland-based company signed an agreement with Harvard University and BioBay in the eastern Chinese city of Suzhou today. The groups aim to develop new treatments for cancer and other diseases, with Roche and BioBay, a Chinese state-owned biotechnology park operator, each contributing about 50 percent of funding to a Harvard project, Roche’s head of pharmaceutical partnering Dan Zabrowski said in an interview.
“What we’re looking for here are research partnership opportunities that will result in products meant not just for China, but for the rest of the globe,” Zabrowski, a member of Roche’s corporate executive committee, said in an interview. He declined to elaborate on the financial details of today’s agreement, Roche’s fourth research accord in China.
--Daryl Loo. Editors: Jason Gale, Lena Lee
To contact Bloomberg News staff for this story: Daryl Loo in Beijing at firstname.lastname@example.org
To contact the editor responsible for this story: Jason Gale at email@example.com